Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alpesh Amin

Showing results (71-80 of 158) with videos related to

Pageof 16
Sort By:
Journal of Medical Economics|July 26, 2013
Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillationAlpesh Amin, Michael Stokes, Ning Wu, et al.
Cardiology and Therapy|August 20, 2014
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke RisksSteve Deitelzweig, Alpesh Amin, Yonghua Jing, et al.
Journal of Medical Economics|March 28, 2012
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trialsSteve Deitelzweig, Alpesh Amin, Yonghua Jing, et al.
The American Journal of Cardiology|October 3, 2008
Implementing critical pathways and a multidisciplinary team approach to cardiovascular disease managementEric D Peterson, Nancy M Albert, Alpesh Amin, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 11, 2013
Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES TrialAlpesh Amin, Steve Deitelzweig, Yonghua Jing, et al.
Journal of Medical Economics|July 23, 2013
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trialsSteve Deitelzweig, Alpesh Amin, Yonghua Jing, et al.
Journal of Thrombosis and Thrombolysis|January 31, 2014
Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trialsAlpesh Amin, Steve Deitelzweig, Yonghua Jing, et al.
Annals of Surgery|April 12, 2021
Analysis of COVID-19 Patients With Acute Respiratory Distress Syndrome Managed With Extracorporeal Membrane Oxygenation at US Academic CentersNinh T Nguyen, Brittany Sullivan, Fabio Sagebin, et al.
The American Journal of the Medical Sciences|May 1, 2022
In-hospital mortality, length of stay, and hospitalization cost of COVID-19 patients with and without hyperkalemiaAlpesh Amin, Rena Moon, Abiy Agiro, et al.
The American Journal of Cardiology|March 14, 2016
Racial Differences in the Prevalence and Outcomes of Atrial Fibrillation in Patients Hospitalized With Heart FailureSubir Bhatia, Mohammad Qazi, Ashwini Erande, et al.
Pageof 16

Showing results (71-80 of 158) with videos related to

Sort By:
Pageof 16
Journal of Medical Economics|July 26, 2013
Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillationAlpesh Amin, Michael Stokes, Ning Wu, et al.
Cardiology and Therapy|August 20, 2014
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke RisksSteve Deitelzweig, Alpesh Amin, Yonghua Jing, et al.
Journal of Medical Economics|March 28, 2012
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trialsSteve Deitelzweig, Alpesh Amin, Yonghua Jing, et al.
The American Journal of Cardiology|October 3, 2008
Implementing critical pathways and a multidisciplinary team approach to cardiovascular disease managementEric D Peterson, Nancy M Albert, Alpesh Amin, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 11, 2013
Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES TrialAlpesh Amin, Steve Deitelzweig, Yonghua Jing, et al.
Journal of Medical Economics|July 23, 2013
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trialsSteve Deitelzweig, Alpesh Amin, Yonghua Jing, et al.
Journal of Thrombosis and Thrombolysis|January 31, 2014
Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trialsAlpesh Amin, Steve Deitelzweig, Yonghua Jing, et al.
Annals of Surgery|April 12, 2021
Analysis of COVID-19 Patients With Acute Respiratory Distress Syndrome Managed With Extracorporeal Membrane Oxygenation at US Academic CentersNinh T Nguyen, Brittany Sullivan, Fabio Sagebin, et al.
The American Journal of the Medical Sciences|May 1, 2022
In-hospital mortality, length of stay, and hospitalization cost of COVID-19 patients with and without hyperkalemiaAlpesh Amin, Rena Moon, Abiy Agiro, et al.
The American Journal of Cardiology|March 14, 2016
Racial Differences in the Prevalence and Outcomes of Atrial Fibrillation in Patients Hospitalized With Heart FailureSubir Bhatia, Mohammad Qazi, Ashwini Erande, et al.
Pageof 16